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Up to one in four patients with CRC de-
velops PM, which is notoriously difﬁcult
to treat. Despite the magnitude of this
clinical challenge, little is known about
the pathophysiology and molecular biol-
ogy of PM.
Emerging data highlight the role of the
peritoneal ecosystem and of the TME
as key drivers of metastatic progression
and treatment resistance.Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer
(CRC) patients. The pathophysiology of colorectal PM remains poorly character-
ized. Also, the efﬁcacy of current treatment modalities, including surgery and in-
traperitoneal (IP) delivery of chemotherapy, is limited. Increasingly, therefore,
efforts are being developed to unravel the PM cascade and at understanding
the PM-associated tumor microenvironment (TME) and peritoneal ecosystem
as potential therapeutic targets. Here, we review recent insights in the structure
and components of the TME in colorectal PM, and discuss how these may trans-
late into novel therapeutic approaches aimed at re-engineering the metastasis-
promoting activity of the stroma.Current treatment strategies, including
surgery and IP chemotherapy, result in
a shift of the ecosystem towards an over-
all immunosuppressive and metastasis
enhancing environment.
Strategies targeting the TME may pre-
vent or reverse peritoneal cancer pro-
gression. Advances in drug delivery
platforms and tissue engineering hold
considerable promise to allow prolonged
stromal targeting.
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CRC represents a major cause of cancer-related mortality worldwide, and approximately 25% of
patients presents with, or will developperitonealmetastasis (PM; see Glossary) [1]. Despite this
high incidence, and in sharp contrast with PM from ovarian cancer, surprisingly little is known
about the biology of colorectal PM. Over the past decades, advances in surgical management
and identiﬁcation of novel therapeutic targets have led to signiﬁcantly improved survival of patients
with colorectal liver and lung metastases [2]. In contrast, however, modern chemotherapy is less
effective in patients with colorectal PM [3]. At the same time, current treatments such as surgery
and IP chemotherapy adversely affect the peritoneal host defense, leading to rapid recurrence in
many patients.
The role of the tumor microenvironment (TME) in cancer progression is increasingly recog-
nized. While the TME of colorectal PM is poorly understood, recent data suggest that the
tumor stroma may harbor targets for re-engineering the adverse TME and for harnessing the pa-
tient’s immune response. These developments are facilitated by the rapidly increasing interest in
novel compounds and biomaterials for IP delivery such as hydrogels and nanomedicine formula-
tions. Here, we review the pathophysiology (Box 1) andmicroenvironment of PM in CRC patients,
discuss the impact of surgery on PM, and provide insights into novel experimental models (Box 2)
and the potential of stromal targeting in these patients.
TME of colorectal PM
As in any solid cancer, the malignant cell population of PM is embedded in, and communicates
with, a tissue consisting of a large array of cellular and acellular components. The cellular compo-
nents include immune cells, vascular cells, and mesenchymal cells, while the acellular compo-
nents include extracellular vesicles (EVs), nanosized fragments of cells containing lipids,
proteins and nucleotides, structural extracellular matrix (ECM) proteins such as collagen, laminin,
ﬁbronectin, and proteoglycans, and the soluble elements including metabolites, growth factors,
cytokines, chemokines, and proteases. For certain elements such as ECM composition, signiﬁ-
cant differences have been identiﬁed between normal colon, primary CRC, and liver metastases236 Trends in Cancer, March 2020, Vol. 6, No. 3 https://doi.org/10.1016/j.trecan.2019.12.008
© 2019 Elsevier Inc. All rights reserved.
Glossary
Chimeric antigen receptor T cells:
expanded T cells from the patient
(autologous) or from a donor
(allogeneic), which are transducedwith a
gene encoding the engineered chimeric
antigen receptor targeting a speciﬁc
tumor antigen, and reinfused in the
patient.
Epithelial-to-mesenchymal
transition or epithelial plasticity: this
process describes the plasticity that
allows cancer cells to change from an
epithelial to a mesenchymal-like
phenotype, together with the acquisition
of invasive behavior, immune evasion,
and therapy resistance. EMT can be
induced by a variety of growth factors,
signaling pathways, and cellular stresses
such as hypoxia, surgery, and
chemotherapy treatment.
Hyperthermic intraperitoneal
chemoperfusion: clinical treatment
method for patients with peritoneal
metastasis: during surgery and
immediately following surgical removal of
Trends in Cancer[4]. However, further deep mapping and biological understanding of these elements in PM of co-
lorectal cancer needsmore in depth research. An interesting study by Ubink and coworkers com-
pared histopathological and molecular characteristics between paired primary colorectal
cancers, and their associated PM. They found a N50% stromal content in 79% of primary can-
cers, compared to only 40% of PM. In addition, the majority of the primary as well as the metasta-
tic tumors was classiﬁed as consensus molecular subtype (CMS) 4 [5].
The role of exosomes in the pathogenesis of PM was recently highlighted. Extracellular vesicles
from CRC cells are enriched in the cell surface glycoprotein CD44, and vesicle transfer of CD44
to MC enhanced cancer cell invasion by inducing the mesothelial cells (MCs) to secrete matrix
metalloproteinase (MMP), resulting in reduced mesothelial barrier activity [6]. EV-associated
small RNAs from peritoneal lavage samples may have prognostic utility in CRC [7].
The most abundant mesenchymal cell types in the neoplastic stroma are cancer-associated ﬁ-
broblasts (CAFs), a heterogeneous population that contributes to tumor initiation, (peritoneal) me-
tastasis and immune escape [8,9]. The origins of CAFs are incompletely elucidated, but they do
not stem from the cancer cell population. The largest source of CAFs are resident subperitoneal
ﬁbroblasts, which are driven to phenotypic diversity by multiple mediators including transforming
growth factor (TGF)-β, tumor necrosis factor-β, and insulin-like growth factor I [10]. Indeed,
in vitro and xenograft mouse models have demonstrated that subperitoneal ﬁbroblasts create a
permissive environment for invasion and metastasis in colorectal PM [11]. Other cell types thatthe tumor bulk, the peritoneal cavity is
ﬁlled with a heated solution of
chemotherapy (usually a platinum
compound or mitomycin C).
Neutrophil extracellular traps: upon
activating signals and conditions,
neutrophils expel nuclear DNA which
forms extracellular web-like structures
decorated with nuclear histones and
proteins, which serve primarily to trap
microbial pathogens. However, recent
data show that NET formation or
NETosis is involved in a number of
pathological conditions including
intravascular thrombosis, respiratory
disease, and cancer metastasis.
Peritoneal metastasis: this speciﬁc
form of cancer metastasis typically
originates from intra-abdominal cancers
and is characterized by the formation of
metastatic cancer nodules on the
mesothelial surfaces, or on the
underlying stroma.
Pressurized intraperitoneal aerosol
chemotherapy: novel treatment
approach in patients with widespread,
unresectable peritoneal metastases,
consisting of intraperitoneal delivery of
chemotherapy as an aerosol, during a
laparoscopic procedure.
Toll-like receptors: these are a family
of receptors that recognize evolutionary
highly conserved danger signals
expressed by pathogens, and constitute
an important part of the innate immune
system. Depending on the receptor and
Box 1. Pathophysiology of Colorectal PM
The pathophysiology of PM can be conceptualized as a stepwise process (Figure I). Isolated cancer cells or clusters of cells
are shed from the surface of the primary cancer; a process that is facilitated by increased solid pressure and by changes in
the activity of cell adhesion molecules such as E-cadherin [69,70]. In hypermethylated colorectal cancer, Zajac and co-
workers observed that peritoneal spread and collective invasion is mediated by cancer spheroids displaying an outward
apical pole, termed tumor spheres with inverted polarity (TSIPs) [71]. Malignant cells or clusters are transported throughout
the peritoneal cavity with the physiological ﬂow of peritoneal free ﬂuid, resulting in a predictable tumor distribution (pelvis,
right paracolic gutter, omentum, and subdiaphragmatic spaces).
The striking tropism of PM for the omentum is poorly understood. Recent data suggest that tumor-derived inﬂammatory
factors stimulate omental neutrophils to release neutrophil extracellular traps (NETs), formed when stressed neutro-
phils expel their protein-studded chromatin to form local snares, and which act as a premetastatic niche [72]. It has also
been suggested that cancer growth is stimulated by the proangiogenic environment of the omental ‘milky spots’, which
consist of immune aggregates and a dense capillary network and that initial cancer cell binding is mediated by a network
of type I collagen ﬁbers overlaying the milky spots [73,74]. In ovarian cancer, the omentum was shown to harbor adipose-
derived mesenchymal stem cells, which alter the metastatic microenvironment via paracrine mechanisms, and promote
disease progression by stimulating proliferation, migration, and chemoresistance [75]. It is unknown whether a similar
mechanism is relevant in CRC.
Loose cancer cells adhere to the MC layer and to the underlying ECM, an active process facilitated by a range of adhesion
molecules. These belong largely to the integrins and their ligands, the proteoglycans such as CD44, the immunoglobulin
superfamily, the blood group antigen proteins, the mucins, and EpCAM [76]. MCs express vascular cell adhesion mole-
cule-1, intercellular adhesion molecule (ICAM)-1, and platelet endothelial cell adhesion molecule-1, but not ICAM-2 or
E-selectin [77,78]. Senescence of peritoneal MCs is associated with increased expression of ICAM-1, and with increased
CRC cell proliferation, migration, and invasion into the submesothelial tissue [79,80]. The expression of mesothelial adhe-
sion molecules (and the resulting cancer cell adhesion) may be considerably enhanced by inﬂammatory stimuli induced by
infection or surgical trauma [81]. NETs were recently shown to play an important role in colon cancer cell metastasis in the
peritoneal cavity, and to regulate colon cancer cell migration and adhesion to ECM proteins [82]. Also, loose cancer cells
gain access to submesothelial tissue at areas of peritoneal discontinuity or MC contraction. Alternatively, cancer cells can
induce retraction and/or apoptosis of MCs. Heath et al. demonstrated FAS-dependent apoptosis of cultured human MCs
induced by SW480 CRC cells [83]. Clusters of ovarian cancer cells induce retraction of MCs via myosin-mediated traction
forces [84]. Once the mesothelial barrier is breached, cancer cells intermingle with ﬁbroblasts and other stromal cell types
in the underlying ECM. Eventually, invasion of the underlying abdominal wall or visceral organ structures will occur, along
with the development of ascites.
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tumor type, agonists of TLR can have
either tumor activating or tumor
suppressing effects.
Tumor microenvironment: this refers
to the cellular, biochemical, and
mechanical constituents that surround
and support the cancer cell population,
with which they form a communicating
ecosystem.
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Figure I. The Peritoneal Metastasis (PM) Cascade. Cancer cells are shed from the primary tumor, either as isolated
cells or as tumor spheres with inverted polarity (TSIPs), and are transported throughout the peritoneal cavity in a clockwise
direction. Cancer cells adhere to the MCs, the glycocalyx, or the underlying stroma, or may be trapped in neutrophil
extracellular traps (NETs). Once the mesothelial layer is breached, cancer cells undergo epithelial-to-mesenchymal
(EMT) plasticity, resulting in a motile and invasive phenotype. Stromal cancer-associated ﬁbroblasts (CAFs) play a
central role in fueling the metastatic process. They may derive from multiple sources such as resident ﬁbroblasts and
MCs, the latter through a process of mesothelial-to-mesenchymal transition (MMT).
Trends in Cancer
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Recent ﬁndings in PM from ovarian cancer suggest that MCs may undergo mesothelial-to-
mesenchymal transition (MMT) to CAFs [12]. Preliminary experiments using patient-derived
material do suggest that MMT occurs in colorectal PM (J. Demuytere et al., unpublished). Re-
cently, in pancreatic tumors, two CAF subtypes were identiﬁed: a population showing nuclear
factor-κB signaling and expression of inﬂammatory cytokines/chemokines termed inﬂammatory
CAF (iCAF), and a population that expresses α-smooth muscle actin and matrix proteins
named myoﬁbroblast CAF (myCAF)[13–15]. Similar heterogeneity in CAF populations has been
observed in breast and lung cancer [16,17]. Whether iCAF, myCAF, or other CAF phenotypes
participate in PM is not known but functional heterogeneity of CAFs may be an emerging feature
of therapy resistance and immune escape of PM.
In the era of immunotherapy, increasing attention goes to the extent and composition of the stro-
mal immune inﬁltrate. In primary CRC, extensive immune cell inﬁltration is observed in the subset
(15%) of patients with deﬁcient mismatch repair, resulting in a high tumor mutational burden and
good response to immune checkpoint inhibitor (ICI) treatment [18]. In patients with colorectal liver
metastasis, the location and extent of immune cells in the invasive margin was shown to predict
response to chemotherapy [19]. The immune composition of colorectal PM remains, however,
largely unexplored. A recent study compared the TME between primary CRC and PM clinical
Trends in Cancersamples, and found that the immune cell inﬁltrate in PM induces senescence and promotes
extensive neovascularization [20]. Also, it appears that although there are multiple immune cells
(including T cells) in the vicinity of colorectal PM cells, these appear to be excluded from the
PM foci (Figure 1).
It is increasingly recognized that speciﬁc subpopulations of immune cells differ not only between
cancer types but also between the primary andmetastatic locations of the same cancer; this con-
cept was recently termed immune contexture [21]. Tumor-associated macrophages (TAMs) are
recruited to the TME by chemokines including CCL2, vascular endothelial growth factor
(VEGF), CCL5, and TGF-β [22]. In general, TAMs stimulate tumor growth andmetastasis by stim-
ulating angiogenesis, priming the premetastatic niche, and exerting immunosuppressive effects
[23]. Recent studies suggest that TAMsmay elicit invasive behavior and epithelial-to-mesenchymal
plasticity in colon cancer cells [24,25]. However, the prognostic signiﬁcance of TAM inﬁltration
differs according to tumor type: a high TAM density is correlated with a worse outcome in gas-
tric cancer, urogenital cancer, and head and neck cancer, but with better survival in CRC [22].
In part, this may be explained by TAM-mediated enhanced response of CRC to chemotherapy
[26]. In ovarian and gastric cancer, TAMs were shown to drive spheroid formation and to pro-
mote peritoneal dissemination [27,28].
The vascular component of the tumor stroma consists of blood vessels, lymphatic channels, and
isolated endothelial cells (ECs). Angiogenic mediators secreted by cancer and stromal cells, in-
cluding VEGFA, placental growth factor, basic ﬁbroblast growth factor (bFGF), and platelet-
derived growth factor (PDGF), drive the formation of microvessels that are morphologically and
functionally abnormal. One of their key characteristics is hyperpermeability, explained by wideBox 2. Novel Experimental Models of Colorectal PM
Syngeneic and xenografted models of colorectal PM can be created by IP injection or implantation of single cells or tissue fragments; the reader is referred to a recently
published overview [85]. Although patient-derived xenografts may retrieve pharmacokinetic and pharmacodynamic information of drugs, these models are expensive,
and do not allow high throughput molecular analyses or drug sensitivity screens. In addition, 2D cancer cell cultures do not recapitulate the phenotypic and genetic het-
erogeneity of the tumor cell population, and segregate cancer cells from interactions with the stromal microenvironment. Novel model systems that allow to faithfully
reproduce the colorectal PM landscape include patient derived tumor organoids, bioengineered scaffolds, and organ-on-chip devices.
Patient-Derived Tumor Organoids
Organoids or tumoroids are self-organizing 3D structures derived from stem cells, cancer cells, and, dependent on the isolation and cultivation procedure,may include TME com-
ponents such as immune cells and CAFs [86]. Patient-derived organoids hold considerable promise for molecular characterization and personalized therapy in CRC [87]. These
self-organized bodies faithfully recapitulate the architecture and immunohistochemistry markers of the source tumor (Figure I). Several groups have succeeded in creating
organoids from patients with colorectal PM, and used these to test drug sensitivity [88–91]. The recent introduction of repeated laparoscopic pressurized intraperitoneal aerosol
chemotherapy (PIPAC) in patients with PM will allow us to predict individual treatment sensitivity, and study the process of emerging drug resistance over time [92].
Bioengineered Scaffolds
Continued developments in the ﬁelds of biomaterials, 3D modeling, and tissue engineering provide new opportunities to study tumor–stroma interactions in PM. The
combination of scaffolds with hydrogels offers a highly innovative tool to construct a TME with the desired cellular and biomechanical properties. Hybrid type I collagen
hydrogel-polylactic acid scaffolds coseeded with cancer cells, and CAFs showed in vitro colonization by heterocellular spheroid formation in the voids of the scaffold
indicating mimicry of the PM architecture at the qualitative, quantitative, and spatial level (Figure I) [93]. Similarly, hybrid RGD-functionalized polyethylene-glycol-based
hydrogel polycaprolactone scaffolds coseeded with cancer cells and MCs showed proliferative and communicative transcriptomic signatures that correlated well with
overall and progression-free survival in high-grade serous ovarian cancer patients [94]. Orthotopic scaffold implantation into immunodeﬁcient mice lead to ascites for-
mation combinedwith omental and liver metastasis. In both scaffoldmodels, patient-derived cell populationsmay be included and further development may allow to use
bioengineered tumors as a platform technology to stratify the design of clinical trials.
Tumor-on-Chip Constructs
A further recent development of organoids as a model system is to connect multiple organoids using microﬂuidic channels. This allows to study the effect of nutrient
distribution and mechanical stress, multiorgan metabolism, drug pharmacokinetics, and the integration of biosensors to monitor drug response [95]. Mazzocchi and
coworkers used peritoneal mesothelioma samples to construct organoids within a tumor-on-a-chip microﬂuidic device, and demonstrated that the results of on-chip
chemotherapy sensitivity screening correlated with those observed in the patients themselves [96].
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Figure I. Model Systems to Study Peritoneal Metastasis (PM). (A) PM can be used to generate 3D tumoroids that express the same diagnostic markers
(homeobox protein, CDX2 and cytokeratin, CK20) as the source tissue. (B) PM tumoroids allow cytotoxic drug testing. (i) Scanning electron micrograph of a PM
organoid (Bar = 50 mm). (ii and iii) Viability assays testing 5-ﬂuorouracil (5FU) ± oxaliplatin (FolFox) and positive cytotoxic control bortezomib (Bortez). (Ci) Confocal
image of a scaffold seeded with eGFP-labeled colorectal cancer cells (green) and tdTomato-labeled CAFs (red). Struts are mainly populated with colorectal cancer
cells in contrast to spheroids that ﬁll up the voids and contain a heterocellular population of cancer cells and CAFs. Inset shows top view of a μCT reconstruction of
polylactic acid scaffold. (Cii) Scanning electron micrograph at an intersection of two struts. Both in Ci and Cii images were taken after 5 weeks of in vitro culture and
dotted line indicates spheroid. Abbreviation: H&E, hematoxylin and eosin.
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Figure 1. The Tumor Microenvironment of Two Clinical Colorectal Peritoneal Metastases. (A) Hematoxylin and eosin staining highlighting the mesothelial
monolayer (black arrow), capillaries (x), arterioles (A), and vein (V). The interface between the submesothelial stroma and tumor stroma is indicated with the broken line.
(B) Multiplex immunohistochemistry highlights immune cell exclusion (white arrow) away from tumor foci (purple arrow). Key: magenta, tumor cells; green, CD8; pink,
CD4; orange, FoxP3; red, PD-1; yellow, PD-L1.
Trends in Cancer
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Trends in Canceror absent intercellular junctions, the presence of lacunae and fenestrations, and incomplete cov-
erage by support cells such as pericytes. As a consequence, large blood components leak into
the interstitium and give rise to elevated oncotic and ﬂuid pressures. The importance of the extent
of angiogenesis in colorectal PM is poorly understood. In a retrospective histological analysis on
PM resection samples, high levels of tissue versican and VEGF expression were associated with
worse overall survival in a multivariable model [29]. However, microvessel density was not corre-
lated with either VEGF expression or survival.
Effects of Surgery on the Peritoneal Ecosystem
It has been established that most of the growth factors, chemokines, and cytokines orchestrating
surgical wound healing also promote tumor (re)growth, epithelial-to-mesenchymal transition
(EMT), which is an important driver of cancer invasion, and angiogenesis [30]. Surgical trauma to
the peritoneum is known to cause adhesions, which may lead to potentially serious complications
such as bowel obstruction. Recent data in a mouse model suggest that the prime mover of
adhesion formation is in fact traumatized MCs, which respond to hypoxia by nuclear activity of
hypoxia-inducible factor (HIF)-1α, resulting in increased expression of podoplanin and mesothelin
[31]. Antibodies neutralizing mesothelin diminish adhesion severity, suggesting potential clinical
translation. Similarly, surgical stress to the peritoneal ecosystem may create a permissive environ-
ment for tumor growth. Clinical peritoneal samples from ovarian carcinoma patients taken at the in-
cision site 1 h after manipulation showed higher abundance of cytokines involved in the
inﬂammatory response [CD54, interleukin (IL)-6, IL-8, serpin E1, and Rantes], cell proliferation,
and negative regulation of cell death [granulocyte colony-stimulating factor (CSF) and complement
component C5/C5a] compared to the samples taken immediately after incision. Importantly, me-
dium from the stressed samples induced cancer cell chemoresistance, a metastatic phenotype,
and resistance to apoptosis. In agreement, the presence of chemokines and cytokines in peritoneal
drain ﬂuids of CRC patients was different in early versus late collections after incision [32]. FGF,
granulocyte–macrophage (GM)-CSF, and IL-6 were the most prevalent postsurgical cytokines,
while CCL2 (MCP-1), CXCL8 (IL-8), and CCL4 (MIP1β) were the most prevalent chemokines im-
mediately after incision. At the end of the procedure, an 11-fold increase of IL-6 and ﬁvefold in-
crease of IL-1β, PDGF, and IL-1 receptor antagonist was observed compared to the starting
point. Similarly, Berkovich et al. sampled drain ﬂuid on consecutive days following colon surgery,
and observed that, in vitro, drain ﬂuid enhanced the migration capacity of colon cancer cells [33].
The perioperative period is characterized by a profound impairment of both innate and adaptive
immunity [34,35]. Speciﬁcally, surgical stress results in an expansion of T regulatory (Treg) cells,
myeloid-derived suppressor cells (MDSCs), and TAMs [36–38]. In addition, surgery results in up-
regulation of PD-1 expression, decreased T-cell proliferation, and impaired dendritic cell (DC) and
natural killer (NK) cell cytotoxicity [39,40]. Angka and coworkers showed a profound reduction in
NK-cell-secreted interferon (IFN)-γ; a cytokine with important roles in controlling infection andme-
tastasis formation [41]. It has been suggested that locoregional hyperthermia may elicit an antitu-
mor immune response, which may overcome the adverse effects of surgery [42]. There are,
however, at present no clinical studies that support this hypothesis in the context of IP therapy.
Anecdotal evidence from drain ﬂuid analyses in a single patient showed that hyperthermic
chemoperfusion (HIPEC) actually reverses tumor-induced NK cell suppression [43].
Laparoscopic surgery, although associated with less surgical trauma, is known to damagemeso-
thelial structure and function by the insufﬂation of cold, dry CO2 gas. The use of warm, humidiﬁed
CO2 gas mitigates expression of cyclo-oxygenase-2, VEGF, and HIF1α, prevents ultrastructural
damage to the MCs and their apical network of microvilli, and impedes tumor cell implantation
and subsequent growth [44,45].Trends in Cancer, March 2020, Vol. 6, No. 3 241
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Intraperitoneal Immunotherapy and Immunomodulation
Advances in the ﬁeld of implantable and injectable biomaterials open exciting new possibilities to
engineer the peritoneal microenvironment. Several forms of IP immune therapy have met with suc-
cess in preclinical models of colorectal PM. These include cell-based therapies, cancer vaccines,
and IP antibodies. Katz and coworkers studied the effects of IP delivery of anti-carcionembryonic
antigen (CEA) chimeric antigen receptor T (CAR-T) cells in a mouse model of colon adenocar-
cinoma [46]. They found that regional delivery resulted in superior antitumor efﬁcacy compared to
systemic administration. Also, the efﬁcacy of anti-CEA CAR-T cells was improved when combined
with targeting of MDSCs and Treg cells. Several IP cancer vaccines have shown promising results
in preclinical colon cancer models. Liang et al. demonstrated the efﬁcacy of a folate receptor alpha
targeted lipoplex loading recombinant IL-15 plasmid in a CT26 colon cancer mouse model [47].
Other promising IP vaccines in preclinical CRC models include a virus-infected cell vaccine ex-
pressing IL-12, and a combination of immune checkpoint inhibitors with IL-18 [48,49]. The
trifunctional antibody catumaxomab contains binding sites for epithelial cell adhesion molecule
(EpCAM) and CD3+ T cells, while the Fc domain binds to type I, IIa, and III Fcγ receptors on
DCs, NKs, and macrophages. The molecule was approved by the European Medicines Agency
for palliation of ascites in EpCAM-positive epithelial cancers. Analysis of clinical ascites samples
showed that treatment with IP catumaxomab enhances the expression of the activation molecules
CD69 and CD38 in T cells, NK cells, andmacrophages, while accumulation of CD8+ T cells into the
peritoneal cavity was enhanced [50]. Also, IP catumaxomab was shown to promote recruitment of
inﬂammatory TH1 cells (capable of degranulating and secreting IFN-γ) and to stimulate expression
of TRAIL by NK cells, and co-stimulatory molecules by monocytes [51]. However, due to its high
immunogenicity rate and narrow indications, commercial sale of catumaxomab was discontinued
in 2017. A comparable approach was reported by Froysnes et al., who successfully treatedKey Figure
Overview of Therapeutic Strategies Aimed at Reengineering the Tumor
Microenvironment of Colorectal Peritoneal Metastases
Trends in Cancer
Figure 2. Abbreviations: CAR-T, chimeric antigen receptor T cell; ECM, extracellular matrix; TGF-β, transforming growth
factor-β; TLR, Toll-like receptor.
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Trends in Cancercolorectal PM patients with IP MOC31PE immunotoxin, consisting of an antibody recognizing
EpCAM conjugated to the potent Pseudomonas exotoxin A [52].
An alternative, promising approach is IP delivery of natural or synthetic compounds that stimulate
innate immunity. Examples include agonists of the Toll-like receptors (cytosine–guanine oligo-
nucleotides, polyinosinic:polycytidylic acid, imidazoquinoline compounds) and activators of
STING (stimulator of interferon genes) such as cyclic dinucleotides [53]. Locoregional delivery
of these compounds in a suitable biomaterial such as a sprayable hydrogel or implantable scaf-
fold in the postsurgical resection bed holds promise to reprogram the postoperative immunosup-
pressive peritoneal environment [54]. Lemdani and coworkers recently reported a combination of
radiofrequency ablation with locoregional immunomodulation in a CT26 mouse model of CRC
[55]. They injected a thermosensitive hydrogel loaded with recombinant GM-CSF and Bacille
Calmette–Guerin (BCG) intralesionally, and when combined with RFA observed a strong immune
response and complete cure of second, untreated tumors implanted in the opposite ﬂank. This
approach is now being tested in a Phase Ib/II study for unresectable colorectal liver metastases
(LICoRN-01, NCT04062721). Similar strategies are currently being pursued in the treatment of
colorectal PM [56]. A Phase I trial of IP ONCOS-102, an oncolytic adenovirus armed with
human GM-CSF and an Ad5/3 chimeric capsid, in combination with an anti-PD-L1 antibody
(durvalumab) is currently ongoing in patients with colorectal PM (NCT02963831).
Taken together, the available data suggest a potential role of IP immunomodulation in patients
with colorectal PM. However, few clinical data are as yet available, and progress is hampered
by the current lack of insight into the immune environment of the peritoneal cavity, and how it is
affected by current treatment approaches.
Targeting the Biomechanical Environment of Colorectal PM
The increased mechanical stress governing the colorectal tumor stroma not only enhances met-
astatic behavior, but also constitutes a signiﬁcant obstacle to systemic as well as IP drug delivery
[57]. As a consequence, therapies aimed at structural remodeling of the stroma may result not
only in biophysical normalization, but also in enhanced drug exposure and reduced metastatic
behavior. Antiﬁbrotic drugs such as pirfenidone inhibit TGF-β-mediated intestinal ﬁbroblast prolif-
eration, and may normalize ﬁbrotic stroma [58]. Direct inhibition of stromal TGF-β signaling was
shown to prevent metastasis formation in mice by patient-derived CRC organoids [59]. Also, re-
cent data suggest a strong link between TGF-β signaling and immunosuppression. Tauriello and
coworkers showed that TGF-β caused immune evasion in a mouse CRC model, and that
pharmacological inhibition restored sensitivity to immune checkpoint inhibition, reduced the
extent of peritoneal carcinomatosis, and blocked the appearance of liver metastases [60]. In ad-
dition, TGF-β-directed therapies inhibit the process of EMT, considered a key driver of the meta-
static process. Multiple TGF-β-directed pharmacological approaches, including small molecule
receptor kinase inhibitors, monoclonal antibodies, antisense oligonucleotides, chimeric proteins,
and vaccines are in early phase clinical trials [61]. A Phase I clinical trial using galunisertib
(LY2157299), a selective TGF-β receptor I inhibitor, is currently recruiting chemotherapy resistant
advanced CRC patients (MoTriColor trial, NCT04031872).
Many solid tumors, including CRC, overexpress FGF and its receptor, and preclinical trials have
shown the potential of blocking this pathway in CRC [62]. A clinical trial of dovitinib, an oral inhib-
itor of FGF and VEGF receptors, failed to show activity in advanced CRC [63]. Targeting
hyaluronic acid, which is upregulated in ﬁbrotic tumors, resulted in lowered solid pressure and im-
proved drug delivery in experimental models. However, a recent clinical trial using recombinant
human hyaluronidase (PEGPH20) in pancreatic cancer showed detrimental effects, raising theTrends in Cancer, March 2020, Vol. 6, No. 3 243
Outstanding Questions
What are the structural and cellular
components of the microenvironment
of colorectal peritoneal metastases,
and how do these affect therapy
response?
How does surgery affect the immune
contexture and peritoneal host defense
in these patients?
What is the potential of organoids and
bioengineered scaffolds as model
systems to study PM?
Can we identify actionable targets in
the biological and mechanical tumor
microenvironment of PM?
What is the potential for intraperitoneal
delivery of novel drug platforms such
as nanomedicine and hydrogels as a
tool to provide immune modulation
and/or immunotherapy?
Trends in Cancerquestion whether stromal elements act to restrain, rather than support, pancreatic cancer cells
[64,65]. Similarly, early clinical trials targeting MMPs, which mediate ECM remodeling, have not
met with success. Enzymes regulating post-translational modiﬁcation of collagen including lysyl
oxidase (LOX), LOX-like 2 (LOXL2), and lysyl hydroxylases have emerged as potential therapeutic
targets [66]. However, the addition of simtuzumab, an antibody to LOXL2, to FOLFIRI did not im-
prove outcome in metastatic KRAS mutant CRC [67].
Despite these initial clinical disappointments, several other novel strategies targeting the biome-
chanical tumor environment in PM are being investigated. The interested reader is referred to a
recent review [68].
Concluding Remarks
The role of the peritoneal microenvironment is increasingly recognized in the pathogenesis and
therapeutic resistance of colorectal PM. The presence of structural ECM components, a pheno-
typic diversity of MCs and CAFs, and impaired innate and adaptive immune cells result in an over-
all state of immunosuppression during PM development and treatment. The biochemical and
biomechanical interactions among cancer cells and the peritoneal microenvironment may dy-
namically evolve in response to any given treatment including surgery and chemotherapy. A bet-
ter understanding of this dynamic reciprocity will reveal the combinatorial signals that support and
promote PM. Preclinical models with the desired cellular and biomechanical properties may
generate novel insights in drug response and resistance. Future PM treatment methods should
include interrogation of the peritoneal microenvironment during therapy, and should consider op-
portunities to prevent or redirect the tumor supportivemicroenvironment associated with PM (see
Outstanding Questions). Inclusion of patient-derived cell populations in bioengineered tumors
may enable personalized therapy testing.
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